Conversely, Pep3 administration led to a partial recovery of the levels of CD8+ TeffPD1+ cells in treated type 1 diabetes PBMC whereas it was ineffective in HD PBMC (Fig 5d). The gene discussed is CD8A; the disease is Huntington disease.